ALAN C MOSES, M.D.
Osteopathic Medicine in Princeton, NJ
License number
New Jersey 44989
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
2
Novo Nordisk Inc, Princeton, NJ 08540
51 Dudley Rd, Newton, MA 02459
51 Dudley Rd, Newton, MA 02459
Phone
(609) 919-7982
Personal information
See more information about ALAN C MOSES at radaris.comName
Address
Phone
59 Goldfinch Dr, Nantucket, MA 02554
9703 Beach Ave, Margate City, NJ 08402
9703 Beach, Margate City, NJ 08402
59 Goldfinch Dr, Nantucket, MA 02554
470 Quinobequin Rd, Waban, MA 02468
Professional information
Small Volume In Vitro Analyte Sensor With Diffusible Or Non-Leachable Redox Mediator
US Patent:
6591125, Jul 8, 2003
Filed:
Jun 27, 2000
Appl. No.:
09/604614
Inventors:
John Bernard Buse - Chapel Hill NC
Alan Charles Moses - Newton Centre MA
Alan Charles Moses - Newton Centre MA
Assignee:
TheraSense, Inc. - Alameda CA
International Classification:
A61B 505
US Classification:
600347, 600345, 600365
Abstract:
A region of skin, other than the fingertips, is stimulated. After stimulation, an opening is created in the skin (e. g. , by lancing the skin) to cause a flow of body fluid from the region. At least a portion of this body fluid is transported to a testing device where the concentration of analyte (e. g. , glucose) in the body fluid is then determined. It is found that the stimulation of the skin provides results that are generally closer to the results of measurements from the fingertips, the traditional site for obtaining body fluid for analyte testing.
Method For Modifying, Diagnosing And Screening For Igf-I Sensitive Cell Barriers
US Patent:
5736400, Apr 7, 1998
Filed:
Dec 2, 1996
Appl. No.:
8/759264
Inventors:
Alan C. Moses - Waban MA
Linda A. Morrow - Newton MA
Jeffrey S. Flier - West Newton MA
Linda A. Morrow - Newton MA
Jeffrey S. Flier - West Newton MA
International Classification:
G01N 3250
US Classification:
435 721
Abstract:
A method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about 7 days wherein the modification effective amount is between about 50. mu. g/kg and less than about 500. mu. g/kg is disclosed. Further disclosed is a method of chronic amelioration or reversal of insulin resistance as well as a method of diagnosing and screening for rhIGF-I sensitive cell barrier properties.
Method For Modifying, Diagnosing, And Screening For Igf-I Sensitive Cell Barrier Properties
US Patent:
5686408, Nov 11, 1997
Filed:
Jul 25, 1994
Appl. No.:
8/279831
Inventors:
Alan C. Moses - Waban MA
Linda A. Morrow - Newton MA
Jeffrey S. Flier - West Newton MA
Linda A. Morrow - Newton MA
Jeffrey S. Flier - West Newton MA
Assignee:
The Beth Israel Hospital Association - Boston MA
International Classification:
A61K 3830
US Classification:
514 3
Abstract:
A method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about 7 days wherein the modification effective amount is between about 50. mu. g/kg and less than about 500. mu. g/kg is disclosed. Further disclosed is a method of chronic amelioration or reversal of insulin resistance as well as a method of diagnosing and screening for rhIGF-I sensitive cell barrier properties.
Methods Of Determining Concentration Of Glucose
US Patent:
7058437, Jun 6, 2006
Filed:
Apr 17, 2003
Appl. No.:
10/418396
Inventors:
John Bernard Buse - Chapel Hill NC, US
Alan Charles Moses - Newton Centre MA, US
Alan Charles Moses - Newton Centre MA, US
Assignee:
TheraSense, Inc. - Alameda CA
International Classification:
A61B 5/05
US Classification:
600347, 600345, 600365
Abstract:
A region of skin, other than the fingertips, is stimulated. After stimulation, an opening is created in the skin (e. g. , by lancing the skin) to cause a flow of body fluid from the region. At least a portion of this body fluid is transported to a testing device where the concentration of analyte (e. g. , glucose) in the body fluid is then determined. It is found that the stimulation of the skin provides results that are generally closer to the results of measurements from the fingertips, the traditional site for obtaining body fluid for analyte testing.
Method For Treating Insulin Resistance With Igf-I
US Patent:
5612312, Mar 18, 1997
Filed:
May 8, 1995
Appl. No.:
8/436633
Inventors:
Alan C. Moses - Waban MA
Linda A. Morrow - Newton MA
Jeffrey S. Flier - West Newton MA
Linda A. Morrow - Newton MA
Jeffrey S. Flier - West Newton MA
International Classification:
A61K 3830
US Classification:
514 12
Abstract:
A method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about 7 days wherein the modification effective amount is between about 50. mu. g/kg and less than about 500. mu. g/kg is disclosed. Further disclosed is a method of chronic amelioration or reversal of insulin resistance as well as a method of diagnosing and screening for rhIGF-I sensitive cell barrier properties.
Methods Of Determining Analyte Concentration
US Patent:
8532731, Sep 10, 2013
Filed:
May 8, 2009
Appl. No.:
12/463183
Inventors:
John Bernard Buse - Chapel Hill NC, US
Alan Charles Moses - Newton Centre MA, US
Alan Charles Moses - Newton Centre MA, US
Assignee:
Abbott Diabetes Care Inc. - Alameda CA
International Classification:
A61B 5/05
US Classification:
600345, 600347, 20440304, 2044031, 205792
Abstract:
A region of skin, other than the fingertips, is stimulated. After stimulation, an opening is created in the skin (e. g. , by lancing the skin) to cause a flow of body fluid from the region. At least a portion of this body fluid is transported to a testing device where the concentration of analyte (e. g. , glucose) in the body fluid is then determined. It is found that the stimulation of the skin provides results that are generally closer to the results of measurements from the fingertips, the traditional site for obtaining body fluid for analyte testing.
Method For Modifying, Diagnosing, And Screening For Igf-I Sensitive Cell Barrier Properties
US Patent:
5637567, Jun 10, 1997
Filed:
May 8, 1995
Appl. No.:
8/437796
Inventors:
Alan C. Moses - Waban MA
Linda A. Morrow - Newton MA
Jeffrey S. Flier - West Newton MA
Linda A. Morrow - Newton MA
Jeffrey S. Flier - West Newton MA
Assignee:
The Beth Israel Hospital Association - Boston MA
International Classification:
A61K 3830
US Classification:
514 12
Abstract:
A method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about 7 days wherein the modification effective amount is between about 50. mu. g/kg and less than about 500. mu. g/kg is disclosed. Further disclosed is a method of chronic amelioration or reversal of insulin resistance as well as a method of diagnosing and screening for rhIGF-I sensitive cell barrier properties.
Drug Administration
US Patent:
4959358, Sep 25, 1990
Filed:
May 23, 1988
Appl. No.:
7/197729
Inventors:
Martin C. Carey - Wellesley MA
Alan C. Moses - Waban MA
Jeffrey S. Flier - West Newton MA
Alan C. Moses - Waban MA
Jeffrey S. Flier - West Newton MA
Assignee:
Beth Israel Hospital Assn. - Boston MA
The Brigham and Womens Hospital, Inc. - Boston MA
The Brigham and Womens Hospital, Inc. - Boston MA
International Classification:
A61K 3156
US Classification:
514171
Abstract:
Compositions and methods useful for the prevention or treatment of a human or animal disorder or for the regulation of the human or animal physiological condition are provided. The compositions used comprise, in admixture, a biologically-effective amount of a drug specific for the disorder or condition and a biocompatible, water-soluble, amphiphilic steroid, other than a natural bile salt, which is capable of increasing drug permeability of the human or animal body surface across which the drug is to be administered, in an amount effective to increase the permeability of the surface to the drug.
Drug Administration
US Patent:
4746508, May 24, 1988
Filed:
May 25, 1984
Appl. No.:
6/614115
Inventors:
Martin C. Carey - Wellesley MA
Alan C. Moses - Waban MA
Jeffrey S. Flier - West Newton MA
Alan C. Moses - Waban MA
Jeffrey S. Flier - West Newton MA
Assignee:
Beth Israel Hospital Assn. - Boston MA
The Brigham and Womens Hospital, Inc. - Boston MA
The Brigham and Womens Hospital, Inc. - Boston MA
International Classification:
A61K 3900, A61K 3156, A61K 3726
US Classification:
424 88
Abstract:
Compositions and methods useful for the prevention or treatment of a human or animal disorder or for the regulation of a human or animal physiological condition are provided. The compositions used comprise, in admixture, a biologically-effective amount of a drug specific for the disorder or condition and a biocompatible, water-soluble, amphiphilic steroid, other than a natural bile salt, which is capable of increasing drug permeability of the human or animal body surface across which the drug is to be administered, in an amount effective to increase the permeability of the surface to the drug.
Drug Administration
US Patent:
4548922, Oct 22, 1985
Filed:
Jun 6, 1983
Appl. No.:
6/501187
Inventors:
Martin C. Carey - Wellesley MA
Alan C. Moses - Waban MA
Jeffrey S. Flier - Newton MA
Alan C. Moses - Waban MA
Jeffrey S. Flier - Newton MA
Assignee:
Beth Israel Hospital - Boston MA
The Brigham & Women's Hospital, Inc. - Boston MA
The Brigham & Women's Hospital, Inc. - Boston MA
International Classification:
A61K 3726, A61K 3156
US Classification:
514 4
Abstract:
A composition useful for the treatment of an animal suffering from a predetermined medical disorder including, in admixture, a medically effective amount of a drug, other than an antibiotic, effective against the medical disorder, and a biocompatible, water-soluble, amphiphilic steroid, other than a bile salt, which is capable of increasing the permeability to the drug of a surface of the animal across which the drug is to be administered, in an amount effective to increase the permeability of the surface to the drug.